Perhaps the smartest news as of late has been the delay in starting the other trials prior to getting the long awaited data from BoM. Albeit possibly astute of the team it still reflects on Managements' understanding of trial designs, fair timing and anticipated costs looking forward. We certainly dont get a gold star for planning the future. I really think monies on the sidelines are affected by our history in prevoius trials and the inabliity to meet expected time targets. Yet we all know that impatience is rarely rewarded in the stock market but if an investor has no concept of timing on return then it comprimises any real involvement. To this day I cant believe we are not in concurent trials incase of a disappointment ahead.,,jmo